Zafgen announced in November results of a completed Phase 2 study of their obesity drug, Beloranib, in severely obese patients (non-pws). Findings from the study demonstrated significant weight loss in 147 obese individuals over a 12 weeks of treatment.
More recently, Zafgen shared results from a small trial involving 17 PWS adults. In the trial, the drug reduced weight and body fat as well as decreased the urge to food seek. Results from the Beloranib study have been reported in both the New York Times and Forbes magazine.